SCHEMBL24997804

SCHEMBL24997804

Cc1ccc(Cl)cc1C(=O)NC(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
HPGD P15428 2/20 0.52
KDM4E B2RXH2 1/20 0.52
MAPK1 P28482 1/20 0.52
HTT P42858 1/20 0.52
KCNA3 P22001 2/20 0.50
ALOX15 P16050 1/20 0.50
GAA P10253 1/20 0.50
ALPL P05186 1/20 0.49
LMNA P02545 1/20 0.48
UTS2R Q9UKP6 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
NPSR1 Q6W5P4 2/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
ALOX5 P09917 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24997807 0.86 FLT1 (0.55) ALDH1A1MEN1KMT2AHPGDKDM4E
SCHEMBL27409724 0.84 ALDH1A1 (0.61) ALDH1A1HPGDKCNA3ALOX15GAA
SCHEMBL21423064 0.83 ALOX5 (0.66) ALDH1A1MEN1KMT2AHPGDKDM4E
SCHEMBL13761455 0.81 FADS1 (0.55) ALDH1A1MEN1KMT2AHPGDKDM4E
SCHEMBL25608334 0.81 POLB (0.55) ALDH1A1MEN1KMT2AHPGDKDM4E
SCHEMBL13754447 0.81 ALDH1A1 (0.72) ALDH1A1MEN1KMT2AHPGDKDM4E
SCHEMBL824657 0.80 JAK2 (0.49) ALDH1A1MEN1KMT2AKDM4EHTT
SCHEMBL12838811 0.80 ALDH1A1 (0.76) ALDH1A1MEN1KMT2AHTTGAA
SCHEMBL23243625 0.79 ALDH1A1 (0.57) ALDH1A1MEN1KMT2AHPGDKDM4E
SCHEMBL23243479 0.79 ALOX5 (0.71) ALDH1A1GAASMN1; SMN2ALOX5TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159446-A1 Methods and Compositions for Targeting Tregs using CCR8 Inhibitors NANJING IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) 2023-05-25 US disclosed
US-20230038589-A1 Methods and compositions for targeting Tregs using CCR8 inhibitors Nanjing Immunophage Biotech Co., Ltd. (CN) 2023-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159446-A1 Methods and Compositions for Targeting Tregs using CCR8 Inhibitors CCR8, CCR1, CCR3 ALDH1A1 2716/4885MEN1 3702/4885KMT2A 2533/4885
US-20230038589-A1 Methods and compositions for targeting Tregs using CCR8 inhibitors CCR8, CCR1, CCR3 ALDH1A1 2716/4885MEN1 3702/4885KMT2A 2533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.